MetaCap

Generate Biomedicines (GENB) vs Ocular Therapeutix (OCUL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Generate Biomedicines is the larger company by market cap ($1.23 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GENB-24.58%OCUL-37.70%
+66%+12%-43%
Feb 27, 20261 yearNov 20, 2026
GENB-24.58%OCUL-37.70%
+41%-0%-41%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GENB versus OCUL key metrics
MetricGENBOCUL
Share price$9.54$5.57
Market cap$1.23B$1.23B
1-day change-8.00%-4.95%
YTD return—-54.12%
1-year return—-54.49%
5-year return—-14.83%
EPS (TTM)$-2.49$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$51.95M
Revenue growth (YoY)—-18.47%
Net income (latest FY)—$-265.94M
Gross margin—87.35%
Operating margin—-519.75%
Net margin—-511.90%
52-week high$22.67$16.44
52-week low$9.40$5.54
Distance from 52-week high-57.92%-66.12%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+183.02%+361.94%
Average volume1.24M3.03M
Shares outstanding129.10M220.02M
Employees312325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Generate Biomedicines

GENB stock →

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees

About Ocular Therapeutix

OCUL stock →

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees

GENB vs OCUL FAQ

Which is bigger, Generate Biomedicines or Ocular Therapeutix?

Generate Biomedicines (GENB) is larger, with a market capitalization of $1.23B compared with $1.23B for Ocular Therapeutix (OCUL).

Are Generate Biomedicines and Ocular Therapeutix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons